Julio Bobes

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8228336/julio-bobes-publications-by-year.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

437 papers	13,458 citations	54 h-index	103 g-index
535 ext. papers	16,908 ext. citations	4 avg, IF	6.05 L-index

#	Paper	IF	Citations
437	Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia.. *Nature Communications*, **2022**, 13, 51	17.4	0
436	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.. *Psychological Medicine*, **2022**, 1-10	6.9	2
435	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study.. *Schizophrenia Bulletin*, **2022**,	1.3	1
434	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2022**, 113, 110440	5.5	0
433	Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia.. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2022**, 15, 22-28	0.2	
432	Validation of a European Spanish-version of the Self-Evaluation of Negative Symptoms (SNS) in patients with schizophrenia.. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2022**, 15, 14-21	0.2	1
431	Does COVID-19 psychological fatigue exist? Results of three online cross-sectional studies conducted in Spain from April 2020 to March 2021.. *Journal of Global Health*, **2022**, 12, 05001	4.3	2
430	Mapping genomic loci implicates genes and synaptic biology in schizophrenia.. *Nature*, **2022**,	50.4	35
429	Is it possible to stage schizophrenia? A systematic review.. *Translational Psychiatry*, **2022**, 12, 197	8.6	
428	Utility and Validity of the Brief Psychiatric Rating Scale (BPRS) as a Transdiagnostic Scale. *Psychiatry Research*, **2022**, 114659	9.9	0
427	Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study. *Psychological Medicine*, **2021**, 51, 1536-1548	6.9	20
426	Study to determine relevant health outcome measures in opioid use disorder: Multicriteria decision analysis. *Revista De Psicologia De La Salud*, **2021**, 33, 109-120	1	
425	Exploring the factor structure of the mini-ICF-APP in an inpatient clinical sample, according to the psychiatric diagnosis. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2021**, 14, 186-195	0.2	
424	A polygenic approach to the association between smoking and schizophrenia. *Addiction Biology*, **2021**, e13104	4.6	0
423	Results of the COVID-19 mental health international for the general population (COMET-G) study. *European Neuropsychopharmacology*, **2021**, 54, 21-40	1.2	12
422	Functional transcranial Doppler: Selection of methods for statistical analysis and representation of changes in flow velocity. *Health Science Reports*, **2021**, 4, e400	2.2	
421	Cognitive functioning in patients with alcohol use disorder who start outpatient treatment. *Revista De Psicologia De La Salud*, **2021**, 33, 161-174	1	1

420	Are older adults also at higher psychological risk from COVID-19?. *Aging and Mental Health*, **2021**, 25, 1297-1304	3.5	40
419	Early Impact of the COVID-19 Outbreak on Sleep in a Large Spanish Sample. *Behavioral Sleep Medicine*, **2021**, 1-16	4.2	9
418	Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study. *Psychological Medicine*, **2021**, 1-9	6.9	3
417	The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study. *Schizophrenia Bulletin*, **2021**, 47, 1674-1684	1.3	3
416	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. *Schizophrenia Bulletin*, **2021**, 47, 1653-1662	1.3	0
415	Psychopathological Symptom Load and Distinguishable Cerebral Blood Flow Velocity Patterns in Patients With Schizophrenia and Healthy Controls: A Functional Transcranial Doppler Study. *Frontiers in Psychiatry*, **2021**, 12, 679021	5	1
414	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2021**, 14, 164-176	0.2	1
413	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. *Revista De Psiquiatría Y Salud Mental*, **2021**, 14, 164-176	2.7	2
412	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. *Psychological Medicine*, **2021**, 51, 623-633	6.9	15
411	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. *CNS Spectrums*, **2021**, 26, 290-298	1.8	4
410	Network structure of psychotic-like experiences in adolescents: Links with risk and protective factors. *Microbial Biotechnology*, **2021**, 15, 595-605	3.3	4
409	Difficulties in delivery and depressive symptomatology in schizophrenia. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2021**, 14, 66-68	0.2	
408	Alcohol use and risk factors for self-harm behavior in Spanish adolescents. *Revista De Psicologia De La Salud*, **2021**, 33, 53-62	1	1
407	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. *European Psychiatry*, **2021**, 64, e25	6	6
406	Difficulties in delivery and depressive symptomatology in schizophrenia. *Revista De Psiquiatría Y Salud Mental*, **2021**, 14, 66-68	2.7	0
405	The training of Psychiatry resident: Summary of the discussion table held during the XXII National Congress of Psychiatry. Spain, 2019. *Revista De Psiquiatría Y Salud Mental*, **2021**, 14, 74-76	2.7	
404	Migration history and risk of psychosis: results from the multinational EU-GEI study. *Psychological Medicine*, **2021**, 1-13	6.9	6
403	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. *Translational Psychiatry*, **2021**, 11, 423	8.6	1

402	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. *CNS Spectrums*, **2021**, 1-8	1.8	1
401	Real-World Functioning in Patients With Schizophrenia: Beyond Negative and Cognitive Symptoms. *Frontiers in Psychiatry*, **2021**, 12, 700747	5	1
400	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. *Schizophrenia Research*, **2021**, 236, 69-79	3.6	0
399	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. *Schizophrenia Research*, **2021**, 236, 19-28	3.6	0
398	Factors associated with alcohol and tobacco consumption as a coping strategy to deal with the coronavirus disease (COVID-19) pandemic and lockdown in Spain. *Addictive Behaviors*, **2021**, 121, 107003	4.2	4
397	Excessive and pathological Internet use - Risk-behavior or psychopathology?. *Addictive Behaviors*, **2021**, 123, 107045	4.2	0
396	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. *Molecular Psychiatry*, **2021**, 26, 4529-4543	15.1	7
395	Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking. *European Psychiatry*, **2021**, 64, e22	6	4
394	The mediating role of impulsivity in the relationship between suicidal behaviour and early traumatic experiences in depressed subjects. *European Psychiatry*, **2021**, 64, S583-S583	6	
393	Insomnia associated with neutrophil/lymphocyte ratio in female patients with schizophrenia. *European Psychiatry*, **2021**, 64, S806-S806	6	
392	Association of traumatic events in childhood, impulsivity and decision-making with previous suicide attempt and/or current suicidal ideation in adult patients with major depressive disorder. *European Psychiatry*, **2021**, 64, S177-S178	6	
391	COVID-19 psychological impact in patients with depressive disorder: Differences based on their age. *European Psychiatry*, **2021**, 64, S674-S675	6	
390	Factors associated with real-world functioning in first stages of schizophrenia disorder. *European Psychiatry*, **2021**, 64, S805-S805	6	
389	P.0564 Active suicidal ideation one year after the beginning of COVID-19 pandemic in a large spanish sample: risk and protective factors. *European Neuropsychopharmacology*, **2021**, 53, S414-S415	1.2	
388	P.0787 Women with schizophrenia have better communication capacity than men, but surprisingly, alogia plays no role on it. *European Neuropsychopharmacology*, **2021**, 53, S575	1.2	
387	P.0786 Cognitive and depressive symptoms lose their impact on real world functioning in the later stages of schizophrenia in both genders. *European Neuropsychopharmacology*, **2021**, 53, S574	1.2	
386	P.0647 Psychological impact in patients with common mental disorders after six months of COVID-19 outbreak. *European Neuropsychopharmacology*, **2021**, 53, S476-S477	1.2	
385	P.0397 Orexin a in patients with bipolar disorder treated with lithium. *European Neuropsychopharmacology*, **2021**, 53, S285-S286	1.2	

384	P.0776 Premorbid childhood and adolescent functioning trajectories in patients with first-episode of schizophrenia using Latent Class Growth Analysis: 2-year follow-up study. *European Neuropsychopharmacology*, **2021**, 53, S566	1.2	
383	Spanish Validation of the MAP-SR: Two Heads Better Than One for the Assessment of Negative Symptoms of Schizophrenia. *Psicothema*, **2021**, 33, 473-480	2	
382	Real-Time Assessment of Stress and Stress Response Using Digital Phenotyping: A Study Protocol. *Frontiers in Digital Health*, **2020**, 2, 544418	2.3	1
381	Farewell letter from the previous Editor of RPSM. *Revista De Psiquiatría Y Salud Mental*, **2020**, 13, 51-52	2.7	
380	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. *Psychological Medicine*, **2020**, 1-9	6.9	13
379	Sex-dependent grades of haematopoietic modulation in patients with major depressive episodes are associated with suicide attempts. *European Neuropsychopharmacology*, **2020**, 40, 17-30	1.2	2
378	Psychiatry residency during the COVID-19 pandemic: Navigating uncharted waters. *Asian Journal of Psychiatry*, **2020**, 53, 102214	6.7	0
377	Influence of coping strategies on the efficacy of YAM (Youth Aware of Mental Health): a universal school-based suicide preventive program. *European Child and Adolescent Psychiatry*, **2020**, 29, 1671-1681	5.5	8
376	Association of cannabinoid receptor genes () polymorphisms and panic disorder. *Anxiety, Stress and Coping*, **2020**, 33, 256-265	3.1	6
375	Neutrophil-to-lymphocyte ratio: A potential new peripheral biomarker of suicidal behavior. *European Psychiatry*, **2020**, 63, e14	6	21
374	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. *Journal of Psychopharmacology*, **2020**, 34, 514-523	4.6	8
373	Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model. *European Neuropsychopharmacology*, **2020**, 33, 158-163	1.2	5
372	The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. *Social Psychiatry and Psychiatric Epidemiology*, **2020**, 55, 645-657	4.5	20
371	Relevant risk factors of repeated suicidal attempts in a sample of outpatients. *Revista De Psiquiatría Y Salud Mental*, **2020**, 13, 11-21	2.7	3
370	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. *Schizophrenia Research*, **2020**, 218, 292-294	3.6	1
369	Doing Nothing is Sometimes Worse: Comparing Avoidant versus Approach Coping Strategies with Peer Victimization and Their Association to Depression and Suicide Ideation. *Journal of School Violence*, **2020**, 19, 456-469	2.5	7
368	Prevalence of Passive Suicidal Ideation in the Early Stage of the Coronavirus Disease 2019 (COVID-19) Pandemic and Lockdown in a Large Spanish Sample. *Journal of Clinical Psychiatry*, **2020**, 81,	4.6	5
367	Validation of a European Spanish-version of the Self-Evaluation of Negative Symptoms (SNS) in patients with schizophrenia. *Revista De Psiquiatría Y Salud Mental*, **2020**,	2.7	2

366	Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia. *Revista De Psiquiatría Y Salud Mental*, **2020**,	2.7	2
365	Twelve-month service use, suicidality and mental health problems of European adolescents after a school-based screening for current suicidality. *European Child and Adolescent Psychiatry*, **2020**, 1	5.5	4
364	Screening for anxiety and depression in Primary Care: Utility of 2 brief scales adapted to the ICD-11-PC. *Revista De Psiquiatría Y Salud Mental*, **2020**,	2.7	1
363	Exploring the factor structure of the mini-ICF-APP in an inpatient clinical sample, according to the psychiatric diagnosis. *Revista De Psiquiatría Y Salud Mental*, **2020**,	2.7	2
362	Life Events Predicting the First Onset of Adolescent Direct Self-Injurious Behavior-A Prospective Multicenter Study. *Journal of Adolescent Health*, **2020**, 66, 195-201	5.8	15
361	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. *Psychological Medicine*, **2020**, 50, 2702-2710	6.9	14
360	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. *Acta Psychiatrica Scandinavica*, **2020**, 141, 541-552	6.5	5
359	Relevant risk factors of repeated suicidal attempts in a sample of outpatients. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2020**, 13, 11-21	0.2	
358	Early Psychological Correlates Associated With COVID-19 in A Spanish Older Adult Sample. *American Journal of Geriatric Psychiatry*, **2020**, 28, 1287-1298	6.5	11
357	A Smart Band for Automatic Supervision of Restrained Patients in a Hospital Environment. *Sensors*, **2020**, 20,	3.8	2
356	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. *Schizophrenia Research*, **2020**, 223, 271-278	3.6	3
355	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. *Psychological Medicine*, **2020**, 1-7	6.9	3
354	P.247 Psychological impact of COVID-19 confinement among people with history of mental disorders (bipolar, anxiety, depression) and general population in Spain. *European Neuropsychopharmacology*, **2020**, 40, S141-S142	1.2	
353	P.502 Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. *European Neuropsychopharmacology*, **2020**, 40, S281-S282	1.2	
352	P.690 Post-traumatic stress symptoms during the COVID-19 in different regions of Spain. *European Neuropsychopharmacology*, **2020**, 40, S393-S394	1.2	
351	The Mediating Role of Impulsivity in the Relationship Between Suicidal Behavior and Early Traumatic Experiences in Depressed Subjects. *Frontiers in Psychiatry*, **2020**, 11, 538172	5	1
350	Suicide. The post-COVID era: A time for action. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2020**, 13, 229-231	0.2	
349	The King's neurologist. *Lancet Neurology, The*, **2020**, 19, 977	24.1	

348	Suicide. The post-COVID era: A time for action. *Revista De Psiquiatría Y Salud Mental*, **2020**, 13, 229-231	2.7	0
347	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. *Epidemiology and Psychiatric Sciences*, **2020**, 29, e182	5.1	11
346	COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls?. *Schizophrenia Research*, **2020**, 223, 192-198	3.6	38
345	Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene. *Schizophrenia Research*, **2020**, 222, 516-519	3.6	
344	Early psychological impact of the 2019 coronavirus disease (COVID-19) pandemic and lockdown in a large Spanish sample. *Journal of Global Health*, **2020**, 10, 020505	4.3	32
343	Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences. *Scientific Reports*, **2020**, 10, 15963	4.9	2
342	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. *Psychological Medicine*, **2020**, 1-13	6.9	2
341	Compulsory admissions of patients with mental disorders: State of the art on ethical and legislative aspects in 40 European countries. *European Psychiatry*, **2020**, 63, e82	6	4
340	Assessing the severity of psychiatric disorders using the Health of the Nation Outcome Scales: An equipercentile linking analysis. *Australian and New Zealand Journal of Psychiatry*, **2020**, 54, 1192-1199	2.6	1
339	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study. *Psychological Medicine*, **2020**, 50, 1884-1897	6.9	17
338	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. *Schizophrenia Bulletin*, **2020**, 46, 517-529	1.3	10
337	A longitudinal examination of the interpersonal theory of suicide and effects of school-based suicide prevention interventions in a multinational study of adolescents. *Journal of Child Psychology and Psychiatry and Allied Disciplines*, **2019**, 60, 1104-1111	7.9	12
336	Predicting real-world functioning in outpatients with schizophrenia: Role of inflammation and psychopathology. *Psychiatry Research*, **2019**, 280, 112509	9.9	6
335	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. *Frontiers in Psychiatry*, **2019**, 10, 676	5	1
334	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. *International Journal of Neuropsychopharmacology*, **2019**, 22, 681-697	5.8	18
333	Association of childhood trauma and genetic variability of CRH-BP and FKBP5 genes with suicidal behavior in bipolar patients. *Journal of Affective Disorders*, **2019**, 255, 15-22	6.6	10
332	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. *World Psychiatry*, **2019**, 18, 173-182	14.4	73
331	Can interleukin-2 and interleukin-1 be specific biomarkers of negative symptoms in schizophrenia?. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2019**, 12, 9-16	0.2	

330	History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders. *European Addiction Research*, **2019**, 25, 111-118	4.6	7
329	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry,the*, **2019**, 6, 427-436	23.3	322
328	CIBERSAM: Ten years of collaborative translational research in mental disorders. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2019**, 12, 1-8	0.2	1
327	Emotion recognition in major depressed patients: Evidence of lack of relationship with suicidal behavior. *European Neuropsychopharmacology*, **2019**, 29, S376-S377	1.2	
326	Could structural changes in the retinal layers be a new biomarker of mental disorders? A systematic review and thematic synthesis. *Revista De Psiquiatr Y Salud Mental*, **2019**, 12, 116-129	2.7	7
325	Dimensional analysis of depressive, anxious and somatic symptoms presented by primary care patients and their relationship with ICD-11 PHC proposed diagnoses. *Psychological Medicine*, **2019**, 49, 764-771	6.9	11
324	Bi-directional longitudinal associations between different types of bullying victimization, suicide ideation/attempts, and depression among a large sample of European adolescents. *Journal of Child Psychology and Psychiatry and Allied Disciplines*, **2019**, 60, 209-215	7.9	58
323	Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial. *Journal of Neural Transmission*, **2019**, 126, 95-99	4.3	1
322	Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). *Acta Psychiatrica Scandinavica*, **2019**, 140, 283-290	6.5	5
321	Clinical staging in severe mental disorders: Bipolar disorder, depression and schizophrenia. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2019**, 12, 106-115	0.2	3
320	"Readiness to Change" Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. *European Addiction Research*, **2019**, 25, 256-262	4.6	1
319	Pharmacological treatment of obsessive compulsive disorder in adults: A clinical practice guideline based on the ADAPTE methodology. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2019**, 12, 77-91	0.2	2
318	Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study. *Journal of Clinical Medicine*, **2019**, 8,	5.1	3
317	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. *Schizophrenia Bulletin*, **2019**, 45, 960-965	1.3	20
316	Factors associated with tobacco consumption in patients with depression. *Revista De Psicologia De La Salud*, **2019**, 31, 298-308	1	2
315	Prevention of recurrent suicidal behavior: Case management and psychoeducation. *Psicothema*, **2019**, 31, 107-113	2	4
314	Predictive factors of alcohol consumption in adolescents: data from 1-year follow-up prospective study. *Revista De Psicologia De La Salud*, **2019**, 31, 52-63	1	1
313	Pharmacological treatment of obsessive compulsive disorder in adults: A clinical practice guideline based on the ADAPTE methodology. *Revista De Psiquiatr Y Salud Mental*, **2019**, 12, 77-91	2.7	2

312	Does ICD-11 improve the epidemiological and nosological purposes of mental, behavioral and developmental disorders?. *Revista De Psicologia De La Salud*, **2019**, 31, 183-188	1	0
311	Spanish validation of the Barcelona TEMPS-A questionnaire in patients with bipolar disorder and general population. *Journal of Affective Disorders*, **2019**, 249, 199-207	6.6	8
310	Assessing the severity of functional impairment of psychiatric disorders: equipercentile linking the mini-ICF-APP and CGI. *Health and Quality of Life Outcomes*, **2019**, 17, 174	3	7
309	P.378 Metabolic syndrome and quality of life in schizophrenia and bipolar disorder. *European Neuropsychopharmacology*, **2019**, 29, S268-S269	1.2	
308	P.586 Comorbid depression in patients with schizophrenia: does it have an impact on their neurocognitive functioning?. *European Neuropsychopharmacology*, **2019**, 29, S407-S408	1.2	
307	Clinical staging in severe mental disorders; bipolar disorder, depression and schizophrenia. *Revista De Psiquiatría Y Salud Mental*, **2019**, 12, 106-115	2.7	11
306	Barriers to complete recovery of major depression: cross-sectional, multi-centre study on clinical practice. RECORD study. *Revista De Psiquiatría Y Salud Mental*, **2019**, 12, 141-150	2.7	
305	Smoking Status and Cost of Illness in Patients with Depressive Disorder Based on the National Health Survey in Spain. *Substance Use and Misuse*, **2019**, 54, 713-723	2.2	2
304	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. *European Psychiatry*, **2019**, 56, 14-34	6	170
303	Latent profile analysis of psychosis liability in a community-derived sample of adolescents: Links with mental health difficulties, suicidal ideation, bipolar-like experiences and psychotic-like experiences. *Microbial Biotechnology*, **2019**, 13, 1111-1120	3.3	5
302	Influence of secondary sources in the Brief Negative Symptom Scale. *Schizophrenia Research*, **2019**, 204, 452-454	3.6	3
301	Early versus late stage schizophrenia. What markers make the difference?. *World Journal of Biological Psychiatry*, **2019**, 20, 159-165	3.8	1
300	Diagnostic consequences of a new category of anxious depression and a reduced duration requirement for anxiety symptoms in the ICD-11 PHC. *Journal of Affective Disorders*, **2019**, 245, 120-125	6.6	6
299	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. *Psychological Medicine*, **2019**, 49, 1378-1391	6.9	42
298	5-HTTLPR-brain-derived neurotrophic factor (BDNF) gene interactions and early adverse life events effect on impulsivity in suicide attempters. *World Journal of Biological Psychiatry*, **2019**, 20, 137-149	3.8	12
297	Can interleukin-2 and interleukin-1 be specific biomarkers of negative symptoms in schizophrenia?. *Revista De Psiquiatría Y Salud Mental*, **2019**, 12, 9-16	2.7	6
296	Spanish validation of the Negative Symptom Assessment-16 (NSA-16) in patients with schizophrenia. *Revista De Psiquiatría Y Salud Mental*, **2018**, 11, 169-175	2.7	2
295	The Network Structure of Schizotypal Personality Traits. *Schizophrenia Bulletin*, **2018**, 44, S468-S479	1.3	41

294	Smoking does not impact social and non-social cognition in patients with first episode psychosis. *Schizophrenia Research*, **2018**, 199, 64-74	3.6	12
293	A cost-effectiveness analysis of school-based suicide prevention programmes. *European Child and Adolescent Psychiatry*, **2018**, 27, 1295-1304	5.5	19
292	Association between genetic variation in the myo-inositol monophosphatase 2 (IMPA2) gene and age at onset of bipolar disorder. *Journal of Affective Disorders*, **2018**, 232, 229-236	6.6	3
291	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. *Psychological Medicine*, **2018**, 48, 2247-2256	6.9	25
290	Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. *Revista De Psiquiatr Y Salud Mental*, **2018**, 11, 130-140	2.7	9
289	Inverse association between negative symptoms and body mass index in chronic schizophrenia. *Schizophrenia Research*, **2018**, 192, 69-74	3.6	15
288	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. *Schizophrenia Research*, **2018**, 193, 188-196	3.6	25
287	Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls. *European Psychiatry*, **2018**, 47, 50-59	6	24
286	Spanish validation of the Negative Symptom Assessment-16 (NSA-16) in patients with schizophrenia. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2018**, 11, 169-175	0.2	
285	Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study. *European Psychiatry*, **2018**, 52, 85-94	6	10
284	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. *Lancet Psychiatry,the*, **2018**, 5, 797-807	23.3	100
283	Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis. *International Journal of Neuropsychopharmacology*, **2018**, 21, 410-422	5.8	10
282	Comorbidity of Physical and Anxiety Symptoms in Adolescent: Functional Impairment, Self-Rated Health and Subjective Well-Being. *International Journal of Environmental Research and Public Health* , **2018**, 15,	4.6	12
281	Correlates of sexual initiation among European adolescents. *PLoS ONE*, **2018**, 13, e0191451	3.7	23
280	Brief assessment of schizotypal traits: A multinational study. *Schizophrenia Research*, **2018**, 197, 182-191	3.6	33
279	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. *JAMA Psychiatry*, **2018**, 75, 36-46	14.5	154
278	S240. DETERMINANT FACTORS OF REAL-WORLD FUNCTIONING IN SCHIZOPHRENIA. *Schizophrenia Bulletin*, **2018**, 44, S420-S420	1.3	78
277	T17. OXIDATIVE STRESS BIOMARKERS AND NEGATIVE DIMENSION IN THE FIRST TEN YEARS OF SCHIZOPHRENIA: A 1-YEAR FOLLOW-UP STUDY. *Schizophrenia Bulletin*, **2018**, 44, S119-S119	1.3	78

276	Obstetric Phenotypes in the Heterogeneity of Schizophrenia. *Journal of Nervous and Mental Disease* , **2018**, 206, 882-886	1.8	9
275	Psychopathology is associated with reproductive health risk in European adolescents. *Reproductive Health*, **2018**, 15, 186	3.5	10
274	Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia. *Psychiatry Research*, **2018**, 269, 688-691	9.9	5
273	F12. INFLAMMATORY BIOMARKERS AND COGNITION IN FIRST EPISODE PSYCHOSIS: GENDER DIFFERENCES. *Schizophrenia Bulletin*, **2018**, 44, S222-S223	1.3	78
272	Characterizing decision-making and reward processing in bipolar disorder: A cluster analysis. *European Neuropsychopharmacology*, **2018**, 28, 863-874	1.2	9
271	Genome wide analysis of rare copy number variations in alcohol abuse or dependence. *Journal of Psychiatric Research*, **2018**, 103, 212-218	5.2	5
270	Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2018**, 11, 130-140	0.2	2
269	Physical activity in European adolescents and associations with anxiety, depression and well-being. *European Child and Adolescent Psychiatry*, **2017**, 26, 111-122	5.5	208
268	Evidence-based national suicide prevention taskforce in Europe: A consensus position paper. *European Neuropsychopharmacology*, **2017**, 27, 418-421	1.2	27
267	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. *European Neuropsychopharmacology*, **2017**, 27, 350-359	1.2	21
266	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. *Schizophrenia Research*, **2017**, 189, 84-90	3.6	30
265	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. *European Neuropsychopharmacology*, **2017**, 27, 647-656	1.2	12
264	Factors associated with different smoking status in European adolescents: results of the SEYLE study. *European Child and Adolescent Psychiatry*, **2017**, 26, 1319-1329	5.5	20
263	Risky Drinkers Underestimate their Own Alcohol Consumption. *Alcohol and Alcoholism*, **2017**, 52, 516-517	3.5	8
262	Primary care physiciansQuse of the proposed classification of common mental disorders for ICD-11. *Family Practice*, **2017**, 34, 574-580	1.9	6
261	Bullying Victimization and Suicide Ideation and Behavior Among Adolescents in Europe: A 10-Country Study. *Journal of Adolescent Health*, **2017**, 61, 179-186	5.8	106
260	Suicide, unemployment, and economic recession in Spain. *Revista De Psiquiatr Y Salud Mental*, **2017**, 10, 70-77	2.7	23
259	EPICOG-SCH: A brief battery to screen cognitive impact of schizophrenia in stable outpatients. *Schizophrenia Research: Cognition*, **2017**, 8, 7-20	2.8	1

258	Suicide, unemployment, and economic recession in Spain. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2017**, 10, 70-77	0.2	3
257	Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. *BMC Psychiatry*, **2017**, 17, 250	4.2	100
256	Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients. *Revista De Psiquiatría Y Salud Mental*, **2017**, 10, 192-196	2.7	11
255	Impact of childhood trauma on cognitive profile in bipolar disorder. *Bipolar Disorders*, **2017**, 19, 363-374	3.8	32
254	Is it Feasible and Effective to Help Patients with Severe Mental Disorders to Quit Smoking?. *European Psychiatry*, **2017**, 41, S32-S33	6	
253	Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1987-1999	4	67
252	Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2017**, 10, 192-196	0.2	1
251	Why prudence is needed when interpreting articles reporting clinical trial results in mental health. *Trials*, **2017**, 18, 143	2.8	8
250	Psychosis risk screening: Validation of the youth psychosis at-risk questionnaire - brief in a community-derived sample of adolescents. *International Journal of Methods in Psychiatric Research*, **2017**, 26,	4.3	7
249	Mental health difficulties and suicidal behaviours among young migrants: multicentre study of European adolescents. *BJPsych Open*, **2017**, 3, 291-299	5	14
248	Substance use or abuse, internet use, psychopathology and suicidal ideation in adolescents. *Revista De Psicologia De La Salud*, **2017**, 29, 97-104	1	33
247	Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset. *Journal of Clinical Psychiatry*, **2017**, 78, 1414-1422	4.6	21
246	Validation of a Spanish version of the Columbia-Suicide Severity Rating Scale (C-SSRS). *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2016**, 9, 134-142	0.2	0
245	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. *Psychological Medicine*, **2016**, 46, 2133-44	6.9	28
244	Effectiveness of pharmacogenetic information in the treatment of major depressive disorder: results from the AB-GEN randomized clinical trial. *European Neuropsychopharmacology*, **2016**, 26, S404-S405	1.3	1
243	Métodos de exploración de la función cognitiva en la práctica clínica. *Psiquiatria Biologica*, **2016**, 23, 29-33	0.2	13
242	Suicide prevention strategies revisited: 10-year systematic review. *Lancet Psychiatry,the*, **2016**, 3, 646-59	23.3	773
241	Pathological Internet Use Is on the Rise Among European Adolescents. *Journal of Adolescent Health* , **2016**, 59, 236-9	5.8	43

240	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. *Pharmacogenomics Journal*, **2016**, 16, 439-45	3.5	25
239	Childhood trauma in suicide attempters: Case-control study. *European Psychiatry*, **2016**, 33, S111-S111	6	2
238	Effects of nicotine abstinence on clinical symptoms. Study at 3 and 6-months follow-up of outpatients with schizophrenia. *European Psychiatry*, **2016**, 33, s261-s262	6	1
237	Psychometric properties of a Spanish-version of the Schizophrenia Objective Functioning Instrument (Sp-SOFI). *International Journal of Clinical and Health Psychology*, **2016**, 16, 58-75	5.1	2
236	Validation of a Spanish version of the Columbia-Suicide Severity Rating Scale (C-SSRS). *Revista De Psiquiatría Y Salud Mental*, **2016**, 9, 134-42	2.7	27
235	It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline. *Schizophrenia Research*, **2016**, 176, 272-280	3.6	17
234	Antipsychotic switching in schizoaffective disorder: A systematic review. *World Journal of Biological Psychiatry*, **2016**, 17, 495-513	3.8	13
233	Association between victimization by bullying and direct self injurious behavior among adolescence in Europe: a ten-country study. *European Child and Adolescent Psychiatry*, **2016**, 25, 1183-1193	5.5	34
232	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. *International Journal of Neuropsychopharmacology*, **2016**, 19,	5.8	21
231	Reasons for Attempted Suicide in Europe: Prevalence, Associated Factors, and Risk of Repetition. *Archives of Suicide Research*, **2016**, 20, 45-58	2.3	27
230	Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. *British Journal of Psychiatry*, **2016**, 208, 87-93	5.4	71
229	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. *PLoS ONE*, **2016**, 11, e0160949	3.7	15
228	Tobacco and cognitive performance in schizophrenia patients: the design of the COGNICO study. *Revista De Psicologia De La Salud*, **2016**, 29, 6-12	1	1
227	Alcoholism and its treatment approach from a citizen perspective. *Revista De Psicologia De La Salud*, **2016**, 28, 163-73	1	4
226	Gender differences in addiction severity. *Revista De Psicologia De La Salud*, **2016**, 28, 221-230	1	5
225	A Review of Quality-of-Life Assessment Measures in Schizophrenia: Limitations and Future Developments **2016**, 65-77		
224	Treatments for Opioid Dependence and Methadone **2016**, 595-602		
223	Pathological Internet Use and Risk-Behaviors among European Adolescents. *International Journal of Environmental Research and Public Health*, **2016**, 13,	4.6	64

222	Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. *Acta Psychiatrica Scandinavica*, **2016**, 133, 386-98	6.5	77
221	Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder. *Acta Psychiatrica Scandinavica*, **2016**, 133, 266-76	6.5	26
220	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2016**, 9, 219-227	0.2	3
219	Smoking cessation programs for persons with schizophrenia: An urgent unmet need. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2016**, 9, 181-184	0.2	
218	Inflammatory and metabolic biomarkers of psychopathological dimensions of schizophrenia. *European Psychiatry*, **2016**, 33, s250-s250	6	1
217	Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. *Psychological Medicine*, **2016**, 46, 291-301	6.9	30
216	Obsessive□ompulsive disorder: The usefulness of a pharmacological practice guideline. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2016**, 9, 131-133	0.2	
215	Multiple somatic symptoms in primary care: A field study for ICD-11 PHC, WHO's revised classification of mental disorders in primary care settings. *Journal of Psychosomatic Research*, **2016**, 91, 48-54	4.1	23
214	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. *Revista De Psiquiatría Y Salud Mental*, **2016**, 9, 219-227	2.7	16
213	Help-seeking behaviour following school-based screening for current suicidality among European adolescents. *Social Psychiatry and Psychiatric Epidemiology*, **2015**, 50, 973-82	4.5	18
212	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. *Schizophrenia Research*, **2015**, 164, 65-73	3.6	75
211	Predictive factors of functional capacity and real-world functioning in patients with schizophrenia. *European Psychiatry*, **2015**, 30, 622-7	6	31
210	School-based suicide prevention programmes: the SEYLE cluster-randomised, controlled trial. *Lancet, The*, **2015**, 385, 1536-44	40	299
209	How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. *Acta Psychiatrica Scandinavica*, **2015**, 132, 122-30	6.5	31
208	Psychometric evaluation of the negative syndrome of schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, **2015**, 265, 559-66	5.1	44
207	The negative syndrome of schizophrenia: three -underlying components are better than two. *Schizophrenia Research*, **2015**, 166, 115-8	3.6	15
206	Aumento de peso y s□drome metab□co. *Psiquiatria Biologica*, **2015**, 22, 3-9	0.2	0
205	Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms. *European Neuropsychopharmacology*, **2015**, 25, 257-64	1.2	39

204	Factors associated with hospitalization after suicide spectrum behaviors: results from a multicenter study in Spain. *Archives of Suicide Research*, **2015**, 19, 17-34	2.3	12
203	Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response: Association With IMPA2, INPP1, and GSK3B Genes. *Journal of Clinical Psychopharmacology*, **2015**, 35, 600-4	1.7	18
202	Reading Books and Watching Films as a Protective Factor against Suicidal Ideation. *International Journal of Environmental Research and Public Health*, **2015**, 12, 15937-42	4.6	6
201	Cognitive Performance associated to functional outcomes in stable outpatients with schizophrenia. *Schizophrenia Research: Cognition*, **2015**, 2, 146-158	2.8	14
200	Predictors of posttreatment drinking outcomes in patients with alcohol dependence. *European Addiction Research*, **2015**, 21, 19-30	4.6	10
199	Pathological Internet use among adolescents: Comparing gamers and non-gamers. *Psychiatry Research*, **2015**, 228, 128-35	9.9	89
198	Assessing and treating alcohol relapse risk in liver transplantation candidates. *Alcohol and Alcoholism*, **2015**, 50, 164-72	3.5	38
197	Response to QRemarkable prevalence of celiac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding studyQ authorsQreply. *Arthritis Research and Therapy*, **2014**, 16, 403	5.7	
196	Hours of sleep in adolescents and its association with anxiety, emotional concerns, and suicidal ideation. *Sleep Medicine*, **2014**, 15, 248-54	4.6	107
195	Spanish consensus on the physical health of patients with depressive disorders. *Revista De Psiquiatr Y Salud Mental*, **2014**, 7, 195-207	2.7	11
194	Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description. *Revista De Psiquiatr Y Salud Mental*, **2014**, 7, 166-78	2.7	7
193	Study protocol of a prevention of recurrent suicidal behaviour program based on case management (PSyMAC). *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2014**, 7, 131-138	0.2	
192	Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2014**, 7, 113-120	0.2	2
191	Life-time prevalence and psychosocial correlates of adolescent direct self-injurious behavior: a comparative study of findings in 11 European countries. *Journal of Child Psychology and Psychiatry and Allied Disciplines*, **2014**, 55, 337-48	7.9	208
190	Pathological Internet use among European adolescents: psychopathology and self-destructive behaviours. *European Child and Adolescent Psychiatry*, **2014**, 23, 1093-102	5.5	121
189	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. *Schizophrenia Research*, **2014**, 159, 107-13	3.6	27
188	Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. *Journal of Affective Disorders*, **2014**, 160, 50-4	6.6	54
187	Suicide prevention in Spain: An uncovered clinical need. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2014**, 7, 1-4	0.2	0

186	EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. *European Psychiatry*, **2014**, 29, 65-82	6	92
185	Spanish adaptation and validation of the Brief Negative Symptoms Scale. *Comprehensive Psychiatry*, **2014**, 55, 1726-9	7.3	45
184	Association between GSK3 gene and increased impulsivity in bipolar disorder. *European Neuropsychopharmacology*, **2014**, 24, 510-8	1.2	19
183	Pro-/antiinflammatory dysregulation in early psychosis: results from a 1-year follow-up study. *International Journal of Neuropsychopharmacology*, **2014**, 18,	5.8	18
182	Alcohol consumption patterns among adolescents are related to family structure and exposure to drunkenness within the family: results from the SEYLE project. *International Journal of Environmental Research and Public Health*, **2014**, 11, 12700-15	4.6	20
181	Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. *Schizophrenia Bulletin*, **2014**, 40, 729-36	1.3	186
180	Immigration and recommended care after a suicide attempt in Europe: equity or bias?. *European Journal of Public Health*, **2014**, 24, 63-5	2.1	4
179	Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?. *British Journal of Clinical Pharmacology*, **2014**, 77, 272-84	3.8	27
178	Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2014**, 7, 166-178	0.2	
177	Spanish consensus on the physical health of patients with depressive disorders. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2014**, 7, 195-207	0.2	1
176	Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study. *Arthritis Research and Therapy*, **2014**, 16, 421	5.7	12
175	Antipsychotic switching in bipolar disorders: a systematic review. *International Journal of Neuropsychopharmacology*, **2014**, 17, 497-507	5.8	25
174	Teacher satisfaction with school and psychological well-being affects their readiness to help children with mental health problems. *Health Education Journal*, **2014**, 73, 382-393	1.5	45
173	Treatment adherence and quality of sleep in schizophrenia outpatients. *International Journal of Psychiatry in Clinical Practice*, **2014**, 18, 70-6	2.4	26
172	Risk-behaviour screening for identifying adolescents with mental health problems in Europe. *European Child and Adolescent Psychiatry*, **2014**, 23, 611-20	5.5	42
171	Patología dual en trastornos de ansiedad: recomendaciones en el tratamiento farmacológico. *Revista De Psicologia De La Salud*, **2014**, 26, 254	1	4
170	Effects of the economic crisis on demand due to mental disorders in Asturias: data from the Asturias Cumulative Psychiatric Case Register (2000-2010). *Actas Espanolas De Psiquiatria*, **2014**, 42, 108-15	0.7	16
169	Child coping, parent coping assistance, and post-traumatic stress following paediatric physical injury. *Child: Care, Health and Development*, **2013**, 39, 171-7	2.8	35

168	The saving and empowering young lives in Europe (SEYLE) randomized controlled trial (RCT): methodological issues and participant characteristics. *BMC Public Health*, **2013**, 13, 479	4.1	49
167	Guilt and depression: two different factors in individuals with negative symptoms of schizophrenia. *European Psychiatry*, **2013**, 28, 327-31	6	17
166	Remarkable prevalence of coeliac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study. *Arthritis Research and Therapy*, **2013**, 15, R201	5.7	21
165	Clinical impact of a gluten-free diet on health-related quality of life in seven fibromyalgia syndrome patients with associated celiac disease. *BMC Gastroenterology*, **2013**, 13, 157	3	22
164	Genetic variability at IMPA2, INPP1 and GSK3 increases the risk of suicidal behavior in bipolar patients. *European Neuropsychopharmacology*, **2013**, 23, 1452-62	1.2	36
163	The new challenge in identifying the negative syndrome of schizophrenia. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2013**, 6, 141-143	0.2	1
162	Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder. *Schizophrenia Research*, **2013**, 150, 421-6	3.6	24
161	P.7.e.003 Sleep in adolescents: association with emotional problems and suicidal ideation. *European Neuropsychopharmacology*, **2013**, 23, S613-S614	1.2	
160	A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. *European Neuropsychopharmacology*, **2013**, 23, 1432-42	1.2	231
159	P.2.d.014 Genetic variability at IMPA2 and INPP1 genes is associated to lithium response in bipolar patients. *European Neuropsychopharmacology*, **2013**, 23, S370-S371	1.2	1
158	Changes in administrative prevalence of mental disorders over a 13-year period in Asturias (northern Spain). *Revista De Psiquiatría Y Salud Mental*, **2013**, 6, 60-6	2.7	8
157	Effectiveness of a multi-component Smoking Cessation Support Programme (McSCSP) for patients with severe mental disorders: study design. *International Journal of Environmental Research and Public Health*, **2013**, 11, 373-89	4.6	5
156	Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. *American Journal of Psychiatry*, **2013**, 170, 852-9	11.9	211
155	Satisfaction with Life of Schizophrenia Outpatients and Their Caregivers: Differences between Patients with and without Self-Reported Sleep Complaints. *Schizophrenia Research and Treatment*, **2013**, 2013, 502172	0.6	10
154	Adolescent subthreshold-depression and anxiety: psychopathology, functional impairment and increased suicide risk. *Journal of Child Psychology and Psychiatry and Allied Disciplines*, **2013**, 54, 670-7	7.9	278
153	Switching to ziprasidone in the clinical practice setting: an open-label study. *International Journal of Psychiatry in Medicine*, **2013**, 45, 125-42	1	7
152	New treatment guidelines for acute bipolar mania: a critical review. *Journal of Affective Disorders*, **2012**, 140, 125-41	6.6	64
151	The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxiety-related traits. *Acta Psychiatrica Scandinavica*, **2012**, 125, 194-202	6.5	35

150	Prevalence of pathological internet use among adolescents in Europe: demographic and social factors. *Addiction*, **2012**, 107, 2210-22	4.6	376
149	P.3.f.002 Epidemiologic naturalistic study to determine the relationship between the Personal and Social Performance (PSP) scale and the perceived sleep quality in schizophrenia. *European Neuropsychopharmacology*, **2012**, 22, S356	1.2	
148	Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study. *European Psychiatry*, **2012**, 27, 267-74	6	15
147	Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. *European Psychiatry*, **2012**, 27, 301-7	6	28
146	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. *European Psychiatry*, **2012**, 27, 114-28	6	27
145	Recommendations for the prevention and management of suicidal behaviour. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2012**, 5, 8-23	0.2	2
144	Psychometric properties of the Spanish version of the Body Weight, Image and Self-Esteem Evaluation Questionnaire in patients with severe mental disorders. *Comprehensive Psychiatry*, **2012**, 53, 1237-42	7.3	3
143	Suicide prevention for youth--a mental health awareness program: lessons learned from the Saving and Empowering Young Lives in Europe (SEYLE) intervention study. *BMC Public Health*, **2012**, 12, 776	4.1	33
142	The state of psychiatry in Spain. *International Review of Psychiatry*, **2012**, 24, 347-55	3.6	3
141	The cost-effectiveness of paliperidone extended release in Spain. *Journal of Medical Economics*, **2012**, 15 Suppl 1, 26-34	2.4	12
140	Functional impairment as a defining feature of: amnestic MCI cognitive, emotional, and demographic correlates. *International Psychogeriatrics*, **2012**, 24, 1494-504	3.4	23
139	Efectividad a largo plazo de los tratamientos de mantenimiento con metadona en personas con adicción a derivados opiáceos. *Revista De Psicologia De La Salud*, **2012**, 24, 179	1	5
138	The incidence of hospital-treated attempted suicide in Oviedo, Spain. *Crisis*, **2012**, 33, 46-53	2.8	15
137	Sexual dysfunction in patients with schizophrenia vs bipolar disorder. *European Psychiatry*, **2011**, 26, 1542-1542		
136	Clinical meaningful outcomes in schizophrenia: remission and recovery. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2011**, 4, 53-65	0.2	
135	Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. *Revista De Psiquiatría Y Salud Mental*, **2011**, 4, 150-68	2.7	21
134	Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?. *Annals of General Psychiatry*, **2011**, 10, 7	3.4	9
133	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. *World Psychiatry*, **2011**, 10, 138-51	14.4	489

132	A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. *Addictive Behaviors*, **2011**, 36, 1184-90	4.2	45
131	Role of serotonergic-related systems in suicidal behavior: Data from a case-control association study. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2011**, 35, 1518-24	5.5	17
130	A cross-cultural comparison between Spain and the USA: temperament and character distribution by sex and age. *Psychiatry Research*, **2011**, 186, 397-401	9.9	10
129	Interconnection between biological abnormalities in borderline personality disorder: use of the Bayesian networks model. *Psychiatry Research*, **2011**, 186, 315-9	9.9	13
128	Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. *Revista De Psiquiatr Y Salud Mental (English Edition)*, **2011**, 4, 9-18	0.2	3
127	Change in psychiatristsQattitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. *European Psychiatry*, **2011**, 26, 305-12	6	15
126	Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. *European Neuropsychopharmacology*, **2011**, 21, 867-75	1.2	24
125	Self-perceived needs are related to violent behavior among schizophrenia outpatients. *Journal of Nervous and Mental Disease*, **2011**, 199, 666-71	1.8	9
124	Psychometric properties of the Spanish version of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) in patients with severe mental disorders. *Journal of Sexual Medicine*, **2011**, 8, 1371-82	1.1	22
123	Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. *Revista De Psiquiatr Y Salud Mental*, **2011**, 4, 9-18	2.7	49
122	Clinical meaningful outcomes in schizophrenia: remission and recovery. *Revista De Psiquiatr Y Salud Mental*, **2011**, 4, 53-65	2.7	11
121	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry*, **2011**, 10, 52-77	14.4	1288
120	Borderline personality traits in nonclinical young adults. *Journal of Personality Disorders*, **2011**, 25, 542-56	2.6	25
119	Topiramate for the treatment of alcohol dependence: comparison with naltrexone. *European Addiction Research*, **2011**, 17, 29-36	4.6	42
118	Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. *European Addiction Research*, **2011**, 17, 262-70	4.6	15
117	Necesidad de evaluaci de la patolog dual en contexto penitenciario. *Revista De Psicologia De La Salud*, **2011**, 23, 37	1	4
116	Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. *International Journal of Neuropsychopharmacology*, **2010**, 13, 305-20	5.8	90
115	Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. *Schizophrenia Research*, **2010**, 119, 101-9	3.6	122

114	Impact of the Spanish Consensus on Physical Health of Patients with Schizophrenia. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2010**, 3, 119-127	0.2	1
113	Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 26-31	5.5	35
112	Measurement Invariance of the Reynolds Depression Adolescent Scale across Gender and Age. *International Journal of Testing*, **2010**, 10, 133-148	1.5	13
111	Impact of substance use on the physical health of patients with bipolar disorder. *Acta Psychiatrica Scandinavica*, **2010**, 121, 437-45	6.5	23
110	Interactions between functional serotonergic polymorphisms and demographic factors influence personality traits in healthy Spanish Caucasians. *Psychiatric Genetics*, **2010**, 20, 171-8	2.9	17
109	Sociodemographic factors associated with personality traits assessed through the TCI. *Personality and Individual Differences*, **2010**, 48, 809-814	3.3	7
108	Saving and empowering young lives in Europe (SEYLE): a randomized controlled trial. *BMC Public Health*, **2010**, 10, 192	4.1	92
107	The general problem of increased somatic comorbidity in bipolar patients **2010**, 9,		78
106	Narcisismo manifiesto, narcisismo encubierto y trastornos de personalidad en una Unidad de Conductas Adictivas: validez predictiva de respuesta a tratamiento. *Revista De Psicologia De La Salud*, **2010**, 22, 107	1	4
105	Validez de la versión española de la Hypersensitive Narcissism Scale (HSNS) en una Unidad de Conductas Adictivas. *Revista De Psicologia De La Salud*, **2010**, 22, 29	1	6
104	Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. *Journal of Clinical Psychiatry*, **2010**, 71, 280-6	4.6	143
103	Psychometric properties of the Revised Physical and Social Anhedonia Scales in non-clinical young adults. *Spanish Journal of Psychology*, **2009**, 12, 815-22	1	29
102	Cardiovascular risk in patients with bipolar disorder. *Journal of Affective Disorders*, **2009**, 115, 302-8	6.6	59
101	Violence among schizophrenia out-patients compliant with medication: prevalence and associated factors. *Acta Psychiatrica Scandinavica*, **2009**, 119, 218-25	6.5	38
100	Polymorphisms of the IL-1 gene complex are associated with alcohol dependence in Spanish Caucasians: data from an association study. *Alcoholism: Clinical and Experimental Research*, **2009**, 33, 2147-53	3.7	16
99	Differential role of serotonergic polymorphisms in alcohol and heroin dependence. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 695-700	5.5	30
98	Remission in schizophrenia: results from a 1-year follow-up observational study. *Schizophrenia Research*, **2009**, 108, 214-22	3.6	44
97	Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. *Schizophrenia Research*, **2009**, 115, 58-66	3.6	62

96	Spanish Consensus on Physical Health in Patients with Bipolar Disorder. *European Psychiatry*, **2009**, 24, 1-1	6	
95	Substance Use and Physical Health in Patients with Bipolar Disorder Under Maintenance Treatment. *European Psychiatry*, **2009**, 24, 1-1	6	1
94	Cardiovascular and Respiratory Comorbidities in Patients with Bipolar Disorder: A Systematic Review. *European Psychiatry*, **2009**, 24, 1-1	6	
93	Nutritional, Metabolic and Endocrine Disorders in Patients with Bipolar Disorder: A Systematic Review. *European Psychiatry*, **2009**, 24, 1-1	6	
92	Gynaecological and Obstetric Comorbidities in Patients with Bipolar Disorder: A Systematic Review. *European Psychiatry*, **2009**, 24, 1-1	6	
91	Spanish Consensus on Physical Health in Patients with Bipolar Disorder. *European Psychiatry*, **2009**, 24, 1-1	6	
90	Role of serotonergic polymorphisms in the clinical severity of the panic disorder. *Revista De Psiquiatría Y Salud Mental*, **2009**, 2, 35-41	2.7	4
89	Psychometric performance of the Oviedo Sleep Questionnaire in patients with severe mental disorder. *Revista De Psiquiatría Y Salud Mental*, **2009**, 2, 169-77	2.7	17
88	Role of serotonergic polymorphisms in the clinical severity of the panic disorder. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2009**, 2, 35-41	0.2	
87	Psychometric performance of the Oviedo Sleep Questionnaire in patients with severe mental disorder. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2009**, 2, 169-177	0.2	
86	P.2.e.009 Gynaecological and obstetric comorbidities in patients with bipolar disorder: a systematic review. *European Neuropsychopharmacology*, **2009**, 19, S453-S454	1.2	
85	P.3.a.025 Influence of knowledge of the Spanish consensus on physical health in schizophrenic patients in clinical practice. *European Neuropsychopharmacology*, **2009**, 19, S494-S495	1.2	
84	P.6.c.005 Benzodiazepines use withdrawal tapering gradually with pregabalin: findings from the medical practice. *European Neuropsychopharmacology*, **2009**, 19, S652	1.2	1
83	Prevalence of Metabolic Syndrome and Coronary Heart Disease Risk in Patients with Schizoaffective Disorder: Clamors Study. *European Psychiatry*, **2009**, 24, 1-1	6	
82	Differences in Personality Traits Evaluated by TCI According to Physical Illness. *European Psychiatry*, **2009**, 24, 1-1	6	
81	Evaluation of symptomatology on schizophrenia. *Medical Psychiatry*, **2009**, 32-38		
80	Using topiramate or naltrexone for the treatment of alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research*, **2008**, 32, 1251-9	3.7	54
79	The prevalence of metabolic syndrome in patients with bipolar disorder. *Journal of Affective Disorders*, **2008**, 106, 197-201	6.6	95

78	Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. *Schizophrenia Research*, **2008**, 99, 23-8	3.6	18
77	A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. *Schizophrenia Research*, **2008**, 104, 1-12	3.6	62
76	Spanish consensus on physical health of patients with bipolar disorder. *Revista De Psiquiatría Y Salud Mental*, **2008**, 1, 26-37	2.7	29
75	Spanish Consensus on Physical Health of Patients With Bipolar Disorder. *Revista De Psiquiatría Y Salud Mental (English Edition)*, **2008**, 1, 26-37	0.2	
74	Is attempted suicide different in adolescent and adults?. *Psychiatry Research*, **2008**, 157, 131-7	9.9	34
73	Association study between obsessive-compulsive disorder and serotonergic candidate genes. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 765-70	5.5	41
72	Association between heroin dependence and 5-HT2A receptor gene polymorphisms. *European Addiction Research*, **2008**, 14, 47-52	4.6	18
71	Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients. *Alcohol and Alcoholism*, **2008**, 43, 516-22	3.5	23
70	Association study of the interleukin-1 gene complex and tumor necrosis factor alpha gene with suicide attempts. *Psychiatric Genetics*, **2008**, 18, 147-50	2.9	8
69	Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts. *Psychiatric Genetics*, **2008**, 18, 213-8	2.9	25
68	Validity and reliability of the Spanish versions of the Bech-Rafaelsen mania and melancholia scales for bipolar disorders. *Acta Psychiatrica Scandinavica*, **2008**, 117, 207-15	6.5	5
67	Remisión sintomática y funcionamiento social/profesional en pacientes con esquizofrenia tratados ambulatoriamente: prevalencia y asociaciones en un estudio transversal. *European Psychiatry (Ed Española)*, **2008**, 15, 65-74		
66	Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. *Schizophrenia Research*, **2007**, 90, 162-73	3.6	157
65	Lack of association between endothelial nitric oxide synthase (NOS3) gene polymorphisms and suicide attempts. *Behavioral and Brain Functions*, **2007**, 3, 32	4.1	5
64	Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD). *Journal of Affective Disorders*, **2007**, 102, 93-9	6.6	34
63	The "Seroquel" Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. *International Journal of Psychiatry in Clinical Practice*, **2007**, 11, 222-32	2.4	
62	The sufficiency of the HAM-D6 as an outcome instrument in the acute therapy of antidepressants in the outpatient setting. *International Journal of Psychiatry in Clinical Practice*, **2007**, 11, 146-50	2.4	5
61	Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2007**, 31, 741-5	5.5	34

60	Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. *European Psychiatry*, **2007**, 22, 490-8	6	86
59	P.3.c.037 Neuropsychological performance and cognitive disability in schizophrenia outpatients. *European Neuropsychopharmacology*, **2007**, 17, S445-S446	1.2	
58	Quality of life in schizophrenic patients. *Dialogues in Clinical Neuroscience*, **2007**, 9, 215-26	5.7	97
57	Quality of Life in Obsessive-Compulsive Disorder **2007**, 293-303		3
56	Interleukin-1 gene complex in schizophrenia: an association study. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2006**, 141B, 678-80	3.5	12
55	P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study. *European Neuropsychopharmacology*, **2006**, 16, S423-S424	1.2	
54	Negative evidences in association between apolipoprotein E polymorphism and panic disorder. *European Psychiatry*, **2006**, 21, 59-61	6	5
53	Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. *European Psychiatry*, **2006**, 21, 34-40	6	59
52	N-acetyltransferase-2 polymorphisms and schizophrenia. *European Psychiatry*, **2006**, 21, 333-7	6	5
51	Neurologic soft signs in borderline personality disorder. *Journal of Clinical Psychiatry*, **2006**, 67, 541-6	4.6	15
50	Psychometric properties of the Spanish version of the screening scale for DSM-IV Generalized Anxiety Disorder of Carroll and Davidson. *Actas Espanolas De Psiquiatria*, **2006**, 34, 83-93	0.7	4
49	Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2005**, 29, 944-51	5.5	9
48	Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting. *Medicina Clínica*, **2005**, 124, 481-6	1	2
47	Quality of life measures in schizophrenia. *European Psychiatry*, **2005**, 20 Suppl 3, S313-7	6	75
46	Serotonin gene polymorphisms in patients with panic disorder. *Actas Espanolas De Psiquiatria*, **2005**, 33, 210-5	0.7	20
45	Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. *British Journal of Psychiatry*, **2004**, 184, 79-83	5.4	46
44	Managing acute exacerbations of schizophrenia: focus on quetiapine. *Current Medical Research and Opinion*, **2004**, 20, 619-26	2.5	29
43	Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2004**, 28, 1287-97	5.5	25

42	Is the biological nature of depressive symptoms in borderline patients without concomitant Axis I pathology idiosyncratic? Sleep EEG comparison with recurrent brief, major depression and control subjects. *Psychiatry Research*, **2004**, 129, 65-73	9.9	24
41	Psychosocial factors associated with cancer behavioural risk in relatives of cancer patients. *European Journal of Cancer Prevention*, **2004**, 13, 105-11	2	3
40	Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. *Addiction Biology*, **2003**, 8, 429-38	4.6	36
39	Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. *Schizophrenia Research*, **2003**, 62, 77-88	3.6	95
38	Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. *European Neuropsychopharmacology*, **2003**, 13, 39-48	1.2	15
37	Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2003**, 27, 473-81	5.5	30
36	Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. *Journal of Sex and Marital Therapy*, **2003**, 29, 125-47	2.7	150
35	Use of cocaine by secondary school students in northern Spain. *European Addiction Research*, **2003**, 9, 138-43	4.6	11
34	Biological nature of depressive symptoms in borderline personality disorder: endocrine comparison to recurrent brief and major depression. *Journal of Psychiatric Research*, **2002**, 36, 137-45	5.2	20
33	2-COM: an instrument to facilitate patient-professional communication in routine clinical practice. *Acta Psychiatrica Scandinavica*, **2002**, 106, 446-52	6.5	19
32	24-Hour opiate detoxification and antagonist induction at home--the QAsturian methodQa report on 1368 procedures. *Addiction Biology*, **2002**, 7, 243-50	4.6	16
31	Evaluating changes in sexual functioning in depressed patients: sensitivity to change of the CSFQ. *Journal of Sex and Marital Therapy*, **2002**, 28, 93-103	2.7	18
30	Apolipoprotein E genotype and schizophrenia: further negative evidence. *Acta Psychiatrica Scandinavica*, **2002**, 105, 71-5	6.5	12
29	Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study. *European Addiction Research*, **2002**, 8, 147-54	4.6	27
28	Effects of carbamazepine on dexamethasone suppression and sleep electroencephalography in borderline personality disorder. *Neuropsychobiology*, **2002**, 45, 113-9	4	7
27	Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs. *International Clinical Psychopharmacology*, **2002**, 17, 287-95	2.2	4
26	Is antipsychotic-induced weight gain related to sexual dysfunction?. *European Neuropsychopharmacology*, **2002**, 12, 282-283	1.2	
25	Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study. *Clinical Drug Investigation*, **2002**, 22, 609-622	3.2	6

24	High degree of tolerability for monotherapy with high doses of quetiapine: a case report. *Journal of Clinical Psychiatry*, **2002**, 63, 1048-9	4.6	11
23	Current status of quality of life assessment in schizophrenic patients. *European Archives of Psychiatry and Clinical Neuroscience*, **2001**, 251 Suppl 2, II38-42	5.1	12
22	Quality of life and disability in patients with obsessive-compulsive disorder. *European Psychiatry*, **2001**, 16, 239-45	6	164
21	Sleep-EEG in borderline patients without concomitant major depression: a comparison with major depressives and normal control subjects. *Psychiatry Research*, **2001**, 105, 87-95	9.9	43
20	Calidad de vida y discapacidad en pacientes con trastorno obsesivo-compulsivo. *European Psychiatry (Ed Española)*, **2001**, 8, 436-442		
19	Developments in the treatment of drug dependence. *Current Opinion in Psychiatry*, **2000**, 13, 333-338	4.9	6
18	Therapeutic advances: Paroxetine for the treatment of social anxiety disorder **2000**, 11, 99-104		12
17	Quality of Life in Obsessive-Compulsive Disorder. *CNS Spectrums*, **2000**, 5, 37-39	1.8	17
16	Validation of the Spanish version of the Changes in Sexual Functioning Questionnaire (CSFQ). *Journal of Sex and Marital Therapy*, **2000**, 26, 119-31	2.7	22
15	The importance of psychosocial interventions and patient involvement in the treatment of schizophrenia. *International Journal of Psychiatry in Clinical Practice*, **2000**, 4, 35-51	2.4	15
14	Sexual dysfunction in depressed patients undergoing treatment with antidepressants. *International Journal of Psychiatry in Clinical Practice*, **2000**, 4, 311-7	2.4	4
13	A European perspective on social anxiety disorder. *European Psychiatry*, **2000**, 15, 5-16	6	70
12	P01.163 For how long can be expected a sustained improvement in schizophrenic patients treated with antipyschotics? A clinical experience with risperidone. *European Psychiatry*, **2000**, 15, 363s-364s	6	
11	P02.320 Safety and effectiveness of olanzapine versus typical antipsychotic drugs in the treatment of inpatients with schizophrenia (Europa study). *European Psychiatry*, **2000**, 15, 409s-409s	6	
10	Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. *British Journal of Psychiatry*, **1999**, 175, 120-6	5.4	162
9	Quality of Life Assessment in Schizophrenia **1999**, 239-248		1
8	Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. *European Psychiatry*, **1998**, 13, 158-63	6	27
7	Quality of Life in Schizophrenia. *European Psychiatry*, **1997**, 12, 116s-116s	6	4

6	Searching for a predictive peripherical biological model in parasuicidal behaviour. *European Psychiatry*, **1997**, 12, 75-81	6	4
5	Brain glucose metabolism in borderline personality disorder. *Journal of Psychiatric Research*, **1997**, 31, 531-41	5.2	144
4	Trends in suicide in the elderly in Asturias (Spain). *European Psychiatry*, **1995**, 10, 339-44	6	2
3	Jumping To Conclusions, General Intelligence, And Psychosis Liability: Findings From The Multi-Centre EU-GEI Case-Control Study		1
2	The independent and combined influence of schizophrenia polygenic risk score and heavy cannabis use on risk for psychotic disorder: A case-control analysis from the EUGEI study.		2
1	Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study. *Psychological Medicine*,1-9	6.9	1